NCT05958199View on ClinicalTrials.gov

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

PHASE1SuspendedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

July 21, 2023

Primary Completion Date

September 20, 2025

Study Completion Date

September 20, 2025

Conditions
Metastatic Malignant Neoplasm
Interventions
DRUG

NPX267

NPX267 will be administered by intravenous infusion every three weeks until documented disease progression or participant withdrawal

Trial Locations (7)

10461

Albert Einstein Medical College Montefiore Medical Center, New York

21287

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore

22031

NEXT Oncology-Fairfax, Fairfax

37203

Sarah Cannon Research Institute Oncology Partners, Nashville

77030

MD Anderson Cancer Center, Houston

78229

NEXT Oncology-San Antonio, San Antonio

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

NextPoint Therapeutics, Inc.

INDUSTRY

NCT05958199 - A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 | Biotech Hunter | Biotech Hunter